April 19, 2026 04:15 pm (IST)
Follow us:
Emerging markets affect Dr Reddy's Laboratories' December quarter performance
Hyderabad, Feb 9 (IBNS) Dr Reddy's Laboratories Ltd announced its consolidated financial results on Tuesday for the quarter ended December 31, 2015, where it posted consolidated revenue of ₹39.7 billion, up 3 per cent from the same period in 2014, largely because the healthy performance in North America Generics (NAG), Europe and India were partially offset by emerging markets, which were impacted by unfavorable macro-economic conditions.
Revenues from the Global Generics segment for the reported quarter was ₹33.6 billion, up 7 per cent from the year-ago quarter, primarily driven by North America, Europe and India.
Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment was ₹5.1 billion in the reported quarter, and declined by 17 per cent from the same quarter a year ago.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Game changer: India’s first Advanced 3D Glass Semiconductor Packaging Unit to be unveiled in Odisha
Sat, Apr 18 2026
Meta eyes first wave of layoffs on May 20: Report
Sat, Apr 18 2026
Adani Group shares rise as Gautam Adani becomes Asia’s richest, overtakes Mukesh Ambani
Fri, Apr 17 2026
Lenskart dress code row: Hijab allowed, bindi restriction triggers backlash; CEO responds
Thu, Apr 16 2026
Rupee rises 9 paise, upside limited by dollar demand
Thu, Apr 16 2026
Sensex, Nifty rise as oil slips on West Asia de-escalation hopes
Thu, Apr 16 2026